Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | BAX | Q07812 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185568 | 0.92 | FABP3 (0.40) | DAGLALTA4HNR1H2BAXPGR | |
| SCHEMBL7190107 | 0.91 | CA12 (0.43) | DAGLALTA4HPGRMAPTLMNA | |
| SCHEMBL7179685 | 0.85 | ALDH1A1 (0.48) | MAPTPTK2BMEN1KMT2ANPSR1 | |
| SCHEMBL7180835 | 0.83 | MEN1 (0.43) | LTA4HNR1H2BAXFFAR1PARP10 | |
| SCHEMBL7174576 | 0.83 | ALDH1A1 (0.50) | MAPTPTK2BMEN1KMT2ANPSR1 | |
| SCHEMBL7182801 | 0.83 | KMT2A (0.46) | MAPTLMNAMEN1KMT2A | |
| SCHEMBL7182551 | 0.82 | LMNA (0.45) | FFAR1MAPTLMNAMEN1KMT2A | |
| SCHEMBL7189087 | 0.81 | PTGS1 (0.51) | FFAR1PARP10SRD5A2LMNA | |
| SCHEMBL7189098 | 0.81 | CA12 (0.47) | LTA4HNR1H2BAXPGRMAPT | |
| SCHEMBL7189899 | 0.80 | KMO (0.42) | DAGLAPGRKMOLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | DAGLA 2370/4885LTA4H 3888/4885NR1H2 63/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | DAGLA 1871/4885LTA4H 3948/4885NR1H2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.